Phenytoin Antibody (301): sc-57973

Phenytoin Antibody (301) is a mouse monoclonal IgG1 antibody that detects Phenytoin protein in non-species specific samples by enzyme-linked immunosorbent assay (ELISA). Anti-Phenytoin antibody (301) is available as a non-conjugated isotype antibody, providing researchers with a reliable tool for studying this important protein. Phenytoin, a widely used antiepileptic drug, plays a crucial role in managing seizures by stabilizing neuronal membranes and preventing excessive excitability in the motor cortex. This stabilization helps mitigate the risk of seizures triggered by environmental changes or increased neuronal stimulation, which can lead to serious neurological consequences. Additionally, Phenytoin undergoes significant post-translational modifications, including glucuronidation, which affects pharmacokinetics and bioavailability. Understanding these modifications is essential for optimizing therapeutic strategies and minimizing adverse effects, such as sedation and cerebellar ataxia, which can occur with Phenytoin overdose. With a long history of clinical use and established safety profile, Phenytoin monoclonal antibody (301) serves as an invaluable resource for researchers investigating the mechanisms of action and effects of Phenytoin in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Phenytoin Antibody (301) References:

1. Phenytoin: effective but insidious therapy for epilepsy in people with intellectual disability.  |  Iivanainen, M. 1998. J Intellect Disabil Res. 42 Suppl 1: 24-31. PMID: 10030428
2. Phenytoin inhibits isolation-induced aggression specifically in rats with low serotonin.  |  Keele, NB. 2001. Neuroreport. 12: 1107-12. PMID: 11338174
3. Aplastic anemia induced by phenytoin: a geriatric case with severe folic acid deficiency.  |  Blain, H., et al. 2002. J Am Geriatr Soc. 50: 396-7. PMID: 12028229
4. A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin.  |  Wang, X. and Patsalos, PN. 2003. Seizure. 12: 330-6. PMID: 12915078
5. The subgingival microflora in phenytoin-induced gingival hyperplasia.  |  Takada, K., et al. 2003. J Periodontal Res. 38: 477-81. PMID: 12941071
6. Impact of phenytoin therapy on the skin and skin disease.  |  Scheinfeld, N. 2004. Expert Opin Drug Saf. 3: 655-65. PMID: 15500423
7. Anti-epileptic drug phenytoin enhances androgen metabolism and androgen receptor expression in murine hippocampus.  |  Meyer, RP., et al. 2006. J Neurochem. 96: 460-72. PMID: 16336225
8. Phenytoin administration by constant intravenous infusion: selective rates of administration.  |  Donovan, PJ. and Cline, D. 1991. Ann Emerg Med. 20: 139-42. PMID: 1996794
9. Phenytoin: neuroprotection or neurotoxicity?  |  Keppel Hesselink, JM. and Kopsky, DJ. 2017. Neurol Sci. 38: 1137-1141. PMID: 28497312
10. Phenytoin: basic and clinical pharmacology.  |  Jones, GL., et al. 1983. Med Res Rev. 3: 383-434. PMID: 6358722
11. Phenytoin and/or stiripentol in pregnancy: infant monkey hyperexcitability.  |  Phillips, NK. and Lockard, JS. 1993. Epilepsia. 34: 1117-22. PMID: 8243366
12. Phenytoin-induced ophthalmoplegia.  |  Spector, RH., et al. 1976. Neurology. 26: 1031-4. PMID: 824568